| Primary |
| Acute Myeloid Leukaemia |
48.3% |
| Acute Lymphocytic Leukaemia |
21.6% |
| B Precursor Type Acute Leukaemia |
5.1% |
| Chemotherapy |
4.5% |
| Myeloid Leukaemia |
2.8% |
| Pain |
2.8% |
| Pyrexia |
2.8% |
| T-cell Type Acute Leukaemia |
1.7% |
| Abdominal Pain |
1.1% |
| Acute Myeloid Leukemia |
1.1% |
| Chloroma |
1.1% |
| Precursor B-lymphoblastic Lymphoma |
1.1% |
| Premedication |
1.1% |
| Prophylaxis |
1.1% |
| Acute Leukaemia |
0.6% |
| Acute Lymphatic Leukemia |
0.6% |
| Acute Lymphoblastic Leukemia |
0.6% |
| Acute Lymphocytic Leukemia |
0.6% |
| Acute Promyelocytic Leukaemia |
0.6% |
| Anaesthetic Complication |
0.6% |
|
| Vomiting |
11.8% |
| Pyrexia |
9.4% |
| Sepsis |
8.2% |
| Blood Bilirubin Increased |
7.1% |
| Jaundice |
5.9% |
| Respiratory Arrest |
5.9% |
| Hypotension |
4.7% |
| Infection |
4.7% |
| Pneumonia |
4.7% |
| Pneumoperitoneum |
4.7% |
| Cardiomyopathy |
3.5% |
| Ejection Fraction Decreased |
3.5% |
| Hyperglycaemia |
3.5% |
| Hypertension |
3.5% |
| Medication Error |
3.5% |
| Pleural Effusion |
3.5% |
| Respiratory Failure |
3.5% |
| Sinus Tachycardia |
3.5% |
| Bacterial Infection |
2.4% |
| Febrile Neutropenia |
2.4% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
36.2% |
| Acute Myeloid Leukaemia |
30.2% |
| Product Used For Unknown Indication |
7.9% |
| Myelodysplastic Syndrome |
5.1% |
| Drug Use For Unknown Indication |
4.0% |
| B Precursor Type Acute Leukaemia |
3.3% |
| Acute Leukaemia |
2.2% |
| Acute Promyelocytic Leukaemia |
1.6% |
| Prophylaxis |
1.5% |
| Chemotherapy |
1.2% |
| Haematological Malignancy |
1.1% |
| T-cell Type Acute Leukaemia |
1.1% |
| Pneumonia |
0.8% |
| Diffuse Large B-cell Lymphoma |
0.7% |
| Myeloid Leukaemia |
0.7% |
| Non-hodgkin's Lymphoma |
0.6% |
| Precursor B-lymphoblastic Lymphoma |
0.5% |
| Stem Cell Transplant |
0.5% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
0.5% |
| Pyrexia |
0.4% |
|
| Sepsis |
16.9% |
| Thrombocytopenia |
9.3% |
| White Blood Cell Count Decreased |
7.2% |
| Infection |
5.9% |
| Vomiting |
5.4% |
| Osteonecrosis |
5.3% |
| Pyrexia |
4.9% |
| Tumour Lysis Syndrome |
4.6% |
| Respiratory Failure |
4.3% |
| Neutropenic Sepsis |
4.1% |
| Multi-organ Failure |
4.0% |
| Neutropenia |
4.0% |
| Pneumonia |
3.7% |
| Venoocclusive Liver Disease |
3.5% |
| Septic Shock |
3.4% |
| Febrile Neutropenia |
3.2% |
| Glioma |
2.8% |
| Hepatotoxicity |
2.5% |
| Pancytopenia |
2.5% |
| Tachycardia |
2.5% |
|
| Concomitant |
| Acute Lymphocytic Leukaemia |
23.4% |
| Acute Myeloid Leukaemia |
22.1% |
| Prophylaxis |
8.7% |
| Product Used For Unknown Indication |
7.6% |
| Lymphoma |
5.6% |
| Drug Use For Unknown Indication |
5.3% |
| Acute Promyelocytic Leukaemia |
3.4% |
| Leukaemia |
2.7% |
| Antifungal Prophylaxis |
2.3% |
| Chemotherapy |
2.3% |
| Nausea |
2.3% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Infection |
1.6% |
| Neoplasm Malignant |
1.6% |
| Pain |
1.6% |
| Pyrexia |
1.6% |
| Sepsis |
1.6% |
| Febrile Neutropenia |
1.5% |
| Hypertension |
1.4% |
| Myelodysplastic Syndrome |
1.4% |
|
| Vomiting |
9.6% |
| Pneumonia |
9.0% |
| Acute Myeloid Leukaemia |
7.8% |
| Pyrexia |
7.2% |
| Thrombocytopenia |
6.6% |
| Sepsis |
6.0% |
| Septic Shock |
6.0% |
| Muscular Weakness |
4.8% |
| Retinal Vein Thrombosis |
4.8% |
| Convulsion |
4.2% |
| Drug Toxicity |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| Retinoic Acid Syndrome |
3.6% |
| Urinary Incontinence |
3.6% |
| Drug Interaction |
3.0% |
| Myelodysplastic Syndrome |
3.0% |
| Neurotoxicity |
3.0% |
| Pancreatitis Acute |
3.0% |
| Rash |
3.0% |
| Soft Tissue Disorder |
3.0% |
|
| Interacting |
| Acute Myeloid Leukaemia |
44.3% |
| Product Used For Unknown Indication |
37.1% |
| Drug Use For Unknown Indication |
18.6% |
|
| Thrombocytopenia |
76.9% |
| Subarachnoid Haemorrhage |
23.1% |
|
